Federal Register: October 28, 2009 (Volume 74, Number 207)
DOCID: fr28oc09-101 FR Doc E9-26001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
NOTICE: NOTICES
DOCID: fr28oc09-101
SUBJECT CATEGORY:
Importer of Controlled Substances; Notice of Application
DOCUMENT SUMMARY:
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on September 4, 2009, Cerilliant
Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 786652402, made application via the Internet to the Drug Enforcement
Administration (DEA) to be registered as an importer of 5MethoxyN,N
diisopropyltryptamine (7439), a basic class of controlled substance listed in schedule I.
The company plans to import small quantities of the listed controlled substance for the manufacture of analytical reference standards.
Any bulk manufacturers who are presently, or are applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement
[[Page 55585]]
Administration, Office of Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 27, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 4374546), all
applicants for registration to import a basic class of any controlled
substance listed in schedule I or II are, and will continue to be,
required to demonstrate to the Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement Administration, that the
requirements for such registration pursuant to 21 U.S.C. 958(a); 21
U.S.C 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E926001 Filed 102709; 8:45 am]
BILLING CODE 441009P
SUMMARY:
Importer of Controlled Substances; Applications
DOCUMENT BODY 2:
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on September 4, 2009, Cerilliant
Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 786652402, made application via the Internet to the Drug Enforcement
Administration (DEA) to be registered as an importer of 5MethoxyN,N
diisopropyltryptamine (7439), a basic class of controlled substance listed in schedule I.
The company plans to import small quantities of the listed controlled substance for the manufacture of analytical reference standards.
Any bulk manufacturers who are presently, or are applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement
[[Page 55585]]
Administration, Office of Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 27, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 4374546), all
applicants for registration to import a basic class of any controlled
substance listed in schedule I or II are, and will continue to be,
required to demonstrate to the Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement Administration, that the
requirements for such registration pursuant to 21 U.S.C. 958(a); 21
U.S.C 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E926001 Filed 102709; 8:45 am]
BILLING CODE 441009P